Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akihito Imai

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Data in Brief|January 1, 2020
Meta-analysis data concerning popularity, theory of mind and interaction in experimentsAkihito Imai
European Journal of Immunology|May 25, 2007
Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51Akihito Imai, Hiroeki Sahara, Yasuaki Tamura, et al.
Cancer Immunology, Immunotherapy : CII|July 14, 2007
Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cellsNaofumi Shinagawa, Koichi Yamazaki, Yasuaki Tamura, et al.
Cellular Immunology|June 1, 2005
Inhibition of CD62L+ T-cell response in vitro via a novel sulfo-glycolipid, beta-SQAG9 liposome that binds to CD62L molecule on the cell surfaceYoshiteru Yamamoto, Hiroeki Sahara, Mika Takenouchi, et al.
Transplant Immunology|June 23, 2007
Effects of a new immunosuppressive agent, beta-SQAG9, in swine kidney transplantationToshiaki Tanaka, Hiroshi Kitamura, Hiroeki Sahara, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Data in Brief|January 1, 2020
Meta-analysis data concerning popularity, theory of mind and interaction in experimentsAkihito Imai
European Journal of Immunology|May 25, 2007
Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51Akihito Imai, Hiroeki Sahara, Yasuaki Tamura, et al.
Cancer Immunology, Immunotherapy : CII|July 14, 2007
Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cellsNaofumi Shinagawa, Koichi Yamazaki, Yasuaki Tamura, et al.
Cellular Immunology|June 1, 2005
Inhibition of CD62L+ T-cell response in vitro via a novel sulfo-glycolipid, beta-SQAG9 liposome that binds to CD62L molecule on the cell surfaceYoshiteru Yamamoto, Hiroeki Sahara, Mika Takenouchi, et al.
Transplant Immunology|June 23, 2007
Effects of a new immunosuppressive agent, beta-SQAG9, in swine kidney transplantationToshiaki Tanaka, Hiroshi Kitamura, Hiroeki Sahara, et al.
Pageof 1